Back to results
US 12,735,479 B2Granted
Monoclonal antibodies against CLDN18.2 and Fc-engineered versions thereof
AssigneeShijiazhuang Yiling Pharmaceutical Co., Ltd.
InventorZhenhua Jia
Life of this patent
Estimating the term…
Abstract
A panel of monoclonal antibodies which specifically bind to CLDN18.2 and do not specifically bind to CLDN18.1, and optionally have an engineered Fc region is provided.
Claims17
A monoclonal antibody which specifically binds to CLDN18.2, comprising:
- a HVR-H1, a HVR-H2 and a HVR-H3 comprised in a VH as set forth in SEQ ID NO:
- 7, and a HVR-L1, a HVR-L2 and a HVR-L3 comprised in a VL as set forth in SEQ ID NO:
- 8.
Dependencies are inferred from the claim text.